Use of cd146 as a molecular marker in the diagnosis, staging or prognosis of neuropsychiatric lupus

A psychiatric and practical technology, applied in the field of neuropsychiatric lupus molecular markers, can solve the problems of ambiguity

Active Publication Date: 2017-03-15
PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI +1
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are no diagnostic methods that can be applied to the diagnosis of NPSLE, and there are no clear indicators for the early prediction of NPSLE

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of cd146 as a molecular marker in the diagnosis, staging or prognosis of neuropsychiatric lupus
  • Use of cd146 as a molecular marker in the diagnosis, staging or prognosis of neuropsychiatric lupus
  • Use of cd146 as a molecular marker in the diagnosis, staging or prognosis of neuropsychiatric lupus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0040] Example:: detection of sCD146 double-antibody sandwich ELISA

[0041] 1) Coating: Dilute the anti-CD146AA1 antibody to 2.5 μg / ml with 0.02M PB (pH 7.25), mix well, add 50 μl per well into a 96-well microtiter plate, and overnight at 4°C.

[0042] 2) Blocking: Shake off the coating solution, control dryness, add 200 μl per well of 2% BSA-PBS into a 96-well ELISA plate, and block at 37° C. for 2 hours.

[0043] 3) Adding samples: shake off the blocking solution, wash 3 times with 0.1% Tween 20-PBS (PBST), and control to dry; add 50 μl of cerebrospinal fluid or serum samples from patients or normal people to each well, incubate at room temperature for 2 hours, wash with PBST for 5 times to wash away non-specific binding.

[0044] 4) The detection antibody biotinylated AA98 was diluted to 2 μg / ml with 2% BSA-PBS, and 50 μL per well was incubated at room temperature for 2 hours.

[0045] 5) Wash off the antibody, add streptavidin-HRP at an appropriate concentration, 50 μl ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of CD 146 as a molecular marker to diagnosis, periodization or prognosis of neuropsychiatric systemic lupus erythematosus (NPSLE), particularly to application of one or more antibodies or antigen combining segments to preparation of reagents for diagnosis, periodization or prognosis of NPSLE, wherein the one or more antibodies or antigen combining segments are combined to CD 146 protein in a selective manner.

Description

technical field [0001] The present invention relates to the field of molecular markers for neuropsychiatric lupus. In particular, the present invention relates to the use of CD146 as a molecular marker in the diagnosis, staging or prognosis of neuropsychiatric lupus. Background technique [0002] Systemic lupus erythematosus (SLE) is an autoimmune disease mediated by autoantibodies involving multiple systems. Neuropsychiatric lupus (Neuropsychiatric systemic lupuserythematosus, NPSLE,) is a common serious complication of SLE, which can involve the central and peripheral nervous system, manifested as a variety of neurological and psychiatric syndromes, and is one of the important causes of death in SLE. At present, the pathogenesis of NPSLE is still uncertain, including vascular disease, autoimmune antibodies, inflammatory mediators, etc., see Boumpas DT, Austin HA, 3rd, FesslerBJ, Balow JE, Klippel JH, Lockshin MD: Systemic lupus erythematosus: emerging concepts. Part 1: R...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/10
Inventor 曾小峰阎锡蕴张令令李梦涛张德玺张莉段红霞罗永挺
Owner PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap